Improved survival with MEK inhibition in BRAF-mutated melanoma.

By K. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, M. Milhem, L. Demidov, J. Hassel, P. Rutkowski, P. Mohr and 15 more. New England Journal of Medicine, 2012

1,998 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/2b591b704303818c0b9f600408133741b9c6b358

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

In Ophthalmology

Nikolaus Schultz

Citations in the corpus

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. (2014, neutral): “Pain in a limb 30 (14) 3 (1) 33 (16) 1 (<1)”
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers (2018, background): “Moreover, MAPK pathway inhibitors including selective MEK and ERK inhibitors are also under active clinical evaluation in patients with breast and other cancer types (Flaherty et al., 2012; Morris et al., 2013).”
An Integrated Mechanistic Model of Pan-Cancer Driver Pathways Predicts Stochastic Proliferation and Death (2017, background): “Combination therapy is a logical and clinically-proven path forward (Flaherty et al., 2012), but rationalizing even just the choice of combinations from among the at least 28 FDA-approved (Wu et al., 2015) targeted small molecule kinase inhibitors, notwithstanding important questions related to the…”
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “00% Improved 4* [139, 140]”
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. (2017, neutral): “Targeting of a node downstream of mutant BRAF (MEK1 or ERK2) was sufficient to induce vertical pathway lethality and in the case of MEK inhibition, this has been recapitulated clinically (Flaherty et al., 2012).”
Harnessing multimodal data integration to advance precision oncology (2021, background): “Active endogenous mutational processes melanoma 43 , EGFR in NSCLC 44 , ERBB2 (also known as HER2 ) in breast cancer 45 , IDH1 in acute myeloid leukaemia (AML) 46 , BRCA1 or BRCA2 in ovarian cancer 47 and prostate cancer 48 and even rare events such as neurotrophic tyrosine kinase (NTRK) fusions 49…”
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Ipilimumab and vemurafenib, dabrafenib and trametinib have substantially improved response rates and/or survival of the patient population included in prospective randomized trials [25, 27, 29, 30].”
Overcoming Endocrine Resistance in Breast Cancer (2020, positive): “Finally, inhibitors of the MAPK pathway (BRAF, MEK, and ERK inhibitors) may overcome endocrine resistance mediated by BRAF and MAP2K1 alterations (Flaherty et al., 2012; Lian et al., 2019; Sullivan et al., 2018).”
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. (2013, background): “5 Introduction Specific inhibitors of RAF and MEK kinases have been developed to target BRAF and RAS mutant tumors (1-6).”